The company is showing operational improvement but remains sub-scale and unprofitable for common shareholders after preferred dividends. Monitor for sustained VBAS revenue acceleration and any reduction in preferred dividend burden. No guidance was provided, limiting the catalyst for a re-rating.
Price Chart
Executive Summary
Vycor Medical reported Q1 2026 revenue of $458,540 (+5% YoY) and swung to a GAAP operating profit of $45,808 from a $(12,806) loss in the prior-year period, driven by higher VBAS sales and lower operating expenses. However, the company remains unprofitable on a net basis after preferred dividends, with a net loss available to common stockholders of $(142,077). The improvement is notable for a micro-cap, but the absolute revenue base is tiny and no guidance was provided.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $458,540, up 5% from $436,378 in Q1 2025
- GAAP operating profit of $45,808 vs. operating loss of $(12,806) in Q1 2025
- Non-GAAP operating profit of $59,788 vs. $20,388 in Q1 2025
- Net loss available to common stockholders of $(142,077), improved from $(200,748) in Q1 2025
- Preferred stock dividends of $162,185 consumed all operating profit, leaving common holders with a loss
- Vycor Medical division (VBAS) revenue grew 5% to $440,441, driven by international markets
- NovaVision division revenue was $18,099, essentially flat YoY
- Gross margin held steady at 82% for both periods
- No guidance or forward-looking financial outlook provided
Financial Impact
Revenue of $458,540, operating profit of $45,808, net loss to common of $(142,077)
Risk Factors
- Preferred stock dividends of $162,185 per quarter consume all operating profit, leaving common holders with a net loss
- NovaVision revenue remains negligible and declining
- No forward guidance provided, limiting investor visibility
- Micro-cap OTC stock with low liquidity and limited analyst coverage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023666 |
| Document: form8-k.htm | 0001493152-26-023666 |
| Document: 0001493152-26-023666-index-headers.html | 0001493152-26-023666 |
| Document: 0001493152-26-023666-index.html | 0001493152-26-023666 |
| Document: 0001493152-26-023666.txt | 0001493152-26-023666 |
| 8-K Data (Synthetic) | 0001493152-26-023666 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 8-K | $0.0690 $0.0670 | ▲ +2.90% | ▲ +1.37% | $0.0430 (+37.68%) |
May 15, 2026 23w ago | 8-K | $0.0700 $0.0700 | · 0.00% | ▼ −2.12% | $0.0430 (−38.57%) |
Mar 31, 2026 29w ago | 8-K | $0.0900 $0.0690 | ▼ −23.33% | ▼ −32.76% | $0.0430 (−52.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers